依达拉奉对脑梗死患者血清IL-6和TNF-α的影响

Clinical study on effects of Yidalafeng on acute cerebral infarction

目的通过随机、对照的临床研究,对依达拉奉治疗急性脑梗死的有效性进行客观评价。方法将发病24h之内就诊的108例急性脑梗死患者随机分为依达拉奉组与对照组。依达拉奉剂量为30mg,静脉滴注2次/d,连用14d;对照组银杏达莫注射液30ml静滴,1次/d,连用14d。评定的终点指标包括脑卒中的临床神经功能缺损程度评分,血清白细胞介素-6(IL-6)水平,肿瘤坏死因子-α(TNF-α)水平。结果与对照组比较,依达拉奉24h内治疗者神经功能评分和IL-6、TNF-α水平下降显著(P<0.01),无出血事件及其他副作用的发生。结论依达拉奉能显著降低急性脑梗死患者血清中炎性细胞因子IL-6、TNF-α的水平。

Objective To assess the safety and efficacy of Yidalafeng in the treatment of acute cerebral infarction by randomized and controlled clinical triM. Methods 108 patients suffered acute cerebral infarction within 24 hours were randomly divided into two groups：Yidalafeng group and control group. Each patient in the Yidalafeng group was treated with Yidalafeng of 30 mg twice everyday for 14 days; while those in the control group were given the Yinxingdano 30 ml/d for 14 days. The end points included Clinical Neurological Deficits Scale of Stroke, the level of plasma TNF-α, IL-6. Results Not only has the Neurological Deficits Scale of Stroke of Yidalafeng group decreased significantly compared with control group （ P 〈 0.01 ）, when Yidalafeng was used within 24 hours. The level of plasma TNF-α, IL-6 in the patients of Yidalafeng group was significantly decreased compared with that of the control group （ P 〈 0.01 ）. Conclusion Yidalafeng treatment could decrease the level of plasma TNF-α, IL-6 significantly , this treatment is a safe and effective for acute cerebral infarction.